ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the... Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and into surrounding tissues.
- Mechanism
- Curator reviewed
ATG002 is an agonist of the nicotinic acetylcholine (nACh) receptor pathway (pro-angiogenic drugs). It stimulates the nACh receptor pathway and could be useful in promoting angiogenesis in disease conditions where there is an insufficient supply of blood.
- Primary indication
- Investigated for use/treatment in diabetic foot ulcers and wounds.Curator reviewed
- Code names
- ATG002
What you can answer from here — as of April 02, 2025
Which companies are running trials of ATG002, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account